Robeco Institutional Asset Management B.V. Lessens Stake in Zimmer Biomet Holdings, Inc. as Research Reports Highlight Differing Stock Ratings

Robeco Institutional Asset Management B.V. has recently disclosed its lessened stake in Zimmer Biomet Holdings, Inc. by 3.8% in the fourth quarter with the Securities and Exchange Commission. Upon selling its shares amounting to 3,366 during the said quarter, Robeco’s asset management firm now owns 86,141 of Zimmer Biomet’s stocks worth $10,983,000 as reported in their most recent SEC filing.

Zimmer Biomet’s latest EPS for the last quarter was $1.88 which surpassed the consensus estimate by $0.05 and had revenue of $1.83 billion compared to their projected $1.76 billion sales for that period. Additionally, it recorded a return on equity of 11.97% and a net margin of 3.33%. The consecutive increase in revenue is evident from a rise of 2.7% compared to the same period last year generating an EPS of $1.95.

Recent research reports have been released on Zimmer Biomet’s stock rating with Oppenheimer raising its price objective to $142 from $120 differentiating itself with an “outperform” rating while Raymond James upgraded its rating from a “market perform” one to an “outperform” and increased its target price to $144 accordingly placing stock momentum at heightened stakes.

Other analysts express caution towards Zimmer Biomet Holdings as UBS Group gave it a sell rating alongside Royal Bank of Canada who upgrade only slightly producing a consensus rating across at “Hold” level given current market trends hence performance metrics remain reserved at this point.

Despite having multiple ratings assigned deemed sell-hold-buy scenarios; this results-driven market indicates firms positioning themselves carefully before making any notable investment movements given financial situations may require further scrutiny moving ahead into the post-crisis era where stakeholders maintain close watch over fiscal performance like quarterly revenues and overall financial health amidst global economies still undergoing recovery.

The Market Trends of Zimmer Biomet: A Closer Look

Zimmer Biomet: A Closer Look at the Company’s Recent Market Trends

Zimmer Biomet Holdings, Inc. (NYSE ZBH) has been experiencing a lot of activity in recent months from institutional investors and hedge funds, who have been adding or reducing their stakes in the company. Fairfield Bush & Co. is among the institutional investors that acquired a new position in shares of Zimmer Biomet during the first quarter worth about $111,000. Other big names include United Bank and Allianz Asset Management GmbH, both of whom lifted positions in shares of Zimmer Biomet in the first quarter.

Despite all this activity, Zimmer Biomet opened Tuesday at $138.83, with a market cap of $29.01 billion. While this represents good growth for the company, some analysts remain cautious about its long-term potential given its high price-to-earnings ratio, which currently stands at 126.21.

On the other hand, several analysts have recently issued reports on Zimmer Biomet recommending investors to purchase stock offerings from the medical equipment provider given its bullish performance trends over Q1 2017. Among these reports include Oppenheimer’s report raising their price objective on Zimmer Biomet from $120.00 to $142.00 and giving the company an “outperform” rating.

Raymond James also upgraded Zimmer Biomet from a “market perform” rating to an “outperform” rating and set a $144.00 target price on the stock after analyzing its low debt-to-equity ratio of 0.43 compared to industry standards.

However, UBS Group was not so enthusiastic about Zimmer Biomet when it started coverage on it in March 2017 with a “sell” rating and set a target price at just $112 on account of Margin pressures it anticipates due to higher start-up costs that will impact gross margins adversely.

All in all though, despite mixed signals as reflected by varied analyst opinions, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $134.19, according to

Recently, Zimmer Biomet disclosed that it would pay out a quarterly dividend, which was paid on April 28th 2017. Shareholders who were of record on March 29th received a $0.24 per share dividend representing an annualized yield of 0.69%.

However, the company is not immune from insider trading as one of its VPs, Chad F. Phipps recently sold 23,045 shares of the company at an average price of $124.50 totaling $2,869,102.

Zimmer Biomet clearly has interesting market trends to watch; although it shows good potential for growth and share value appreciation in the near future but investors must be vigilant about any negative indications that may point towards drawbacks down the line.

Related Posts